Sector News

Bristol-Myers Squibb names Peter J. Arduini to board of directors

March 4, 2016
Life sciences

Bristol-Myers Squibb Company today announced that its Board of Directors has elected Peter J. Arduini to the Board, effective April 1, 2016. Mr. Arduini will serve as a member of the Audit Committee of the Board of Directors, effective May 3, 2016.

Mr. Arduini, 51, is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company. He joined Integra LifeSciences in 2010 as president and chief operating officer and director, and was named CEO in 2012. Mr. Arduini brings more than 25 years of global experience in medical device technology and pharmaceutical businesses, and has led operations in China, Europe, Japan and the U.S. Before joining Integra, Mr. Arduini was corporate vice president and president of Medication Delivery, Baxter Healthcare, which he joined in 2005. At Baxter, he was responsible for a portfolio focused on the inpatient acute care hospital market. Prior to joining Baxter, Mr. Arduini was responsible for the functional imaging business at General Electric Healthcare, where he spent 15 years assuming increasing levels of responsibility. Mr. Arduini serves on the Board of Directors of ADVAMED, the Advanced Medical Technology Association, and MDIC, the Medical Device Innovation Consortium. Mr. Arduini received his bachelor’s degree in marketing from Susquehanna University and a master’s in management from Northwestern University’s Kellogg School of Management.

“Pete is a confident and engaging leader who has delivered tremendous results throughout his career,” said Lamberto Andreotti, chairman, Bristol-Myers Squibb. “His commercial, financial and operational experience, along with a deep understanding of healthcare, make him an ideal choice for our Board. I look forward to his contributions.”

“Pete brings significant healthcare experience, unwavering integrity and a focus on helping patients,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “Bristol-Myers Squibb will benefit from his insights as a strategic leader, and I am excited to have him join our Board.”

Source: Bristol-Myers Squibb

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach